SARS-CoV-2假病毒包装系统 | ||||||
品牌 | Code No. | 产品名称 | 包装量 | 价格(元) | 说明书 | 数量 |
Clontech | 632668 | Lenti-X™ SARS-CoV-2 Packaging Single Shots (WT Spike, Full Length) | 12 Rxns | ¥12,496 | ||
Clontech | 632669 | Lenti-X™ SARS-CoV-2 Packaging Single Shots (D614G Spike, Full Length) | 12 Rxns | ¥12,496 | ||
Clontech | 631292 | Lenti-X™ SARS-CoV-2 Packaging Single Shots (B.1.351 Spike, Full Length) | 12 Rxns | ¥12,710 | ||
Clontech | 632670 | Lenti-X™ SARS-CoV-2 Packaging Single Shots (WT Spike, Truncated) | 12 Rxns | ¥12,496 | ||
Clontech | 632671 | Lenti-X™ SARS-CoV-2 Packaging Single Shots (D614G Spike, Truncated) | 12 Rxns | ¥12,496 | ||
Clontech | 631293 | Lenti-X™ SARS-CoV-2 Packaging Single Shots (B.1.351 Spike, Truncated) | 12 Rxns | ¥12,710 | ||
Clontech | 631295 | Lenti-X™ SARS-CoV-2 Packaging Single Shots (Universal) | 16 Rxns | ¥13,404 | ||
Clontech | 632672 | Lenti-X™ SARS-CoV-2 Packaging Mix (WT Spike, Full Length) | 12 Rxns | ¥10,004 | ||
Clontech | 632673 | Lenti-X™ SARS-CoV-2 Packaging Mix (D614G Spike, Full Length) | 12 Rxns | ¥10,004 | ||
Clontech | 631290 | Lenti-X™ SARS-CoV-2 Packaging Mix (B.1.351 Spike, Full Length) | 12 Rxns | ¥10,219 | ||
Clontech | 632674 | Lenti-X™ SARS-CoV-2 Packaging Mix (WT Spike, Truncated) | 12 Rxns | ¥10,004 | ||
Clontech | 632675 | Lenti-X™ SARS-CoV-2 Packaging Mix (D614G Spike, Truncated) | 12 Rxns | ¥10,004 | ||
Clontech | 631291 | Lenti-X™ SARS-CoV-2 Packaging Mix (B.1.351 Spike, Truncated) | 12 Rxns | ¥10,219 | ||
Clontech | 632676 | Lenti-X™ SARS-CoV-2 Packaging Mix (No-Envelope Control) | 6 Rxns | ¥4,844 |
开发COVID-19疗法的一个共同目标就是要证明对SARS-CoV-2病毒的感染具有抑制作用。基于安全措施考虑,目前研究人员大多使用带有SARS-CoV-2刺突蛋白(spike protein)的假病毒(Ni et al. 2020, Shang et al. 2020)替代SARS-CoV-2活病毒开展研究。我们对Lenti-X包装系统进行了优化,这样可以很方便地制备高滴度的spike-假慢病毒,为这些研究工作提供支持。 |
|||||||||||||||||||||
Lenti-X SARS-CoV-2 Packaging Single Shots是一种假型慢病毒包装系统,用于简便制备具有SARS-CoV-2刺突蛋白作为包膜蛋白的假型慢病毒,有两种类型产品可供选择。 |
|||||||||||||||||||||
Lenti-X SARS-CoV-2 Packaging Single Shots (Universal)使您能够轻松灵活地制备任何所需要的SARS-CoV-2刺突蛋白变体的高滴度假型慢病毒。只需将任意所需的SARS-CoV-2刺突蛋白变体序列克隆到所提供的表达载体中,用灭菌水稀释所选择的表达载体,然后将混合物添加到试剂盒中提供的单次反应管中。然后,将重组后的转染混合物添加至10 cm培养皿培养的包装细胞中。为方便使用,我们提供分别编码截短的SARS-CoV-2刺突蛋白变体D614G、B.1.1.7和B.1.351的三个质粒。使用提供的刺突蛋白变体序列作为模板和pEmpty载体,通过简便的一步In-Fusion Snap Assembly反应可以轻松构建所需要的SARS-CoV-2刺突蛋白变体。 |
|||||||||||||||||||||
其它Lenti-X SARS-CoV-2 Packaging Single Shots试剂盒包括:含有Xfect转染试剂和慢病毒包装质粒的冻干混合物,慢病毒包装质粒携带四种不同刺突蛋白变体中的其中一种;表达绿色荧光蛋白质ZsGreen1和荧光素酶报告基因的转移载体;制备缺少包膜蛋白慢病毒粒子的转染混合物(通常用作阴性对照)。使用Lenti-X SARS-CoV-2 Packaging Single Shots试剂盒,通过简便的一步法即可获得高滴度SARS-CoV-2假病毒:只需将含有您选择的转移载体的水溶液添加至单管中,然后使用重组后的转染混合物转染培养在10厘米培养皿中的包装细胞Lenti-X 293T Cell Line(Code No. 632180)。转染后48–72小时收集病毒上清液。 |
|||||||||||||||||||||
有多种包装系统可供选择,可制备带有6种不同SARS-CoV-2刺突蛋白变体的病毒粒子: | |||||||||||||||||||||
· WT Spike, Full Length—野生型(全长),来源于新型冠状病毒SARS-CoV-2 Wuhan-Hu-1分离株 (NC_045512.2) , 我们对密码子进行了优化,可以在哺乳动物细胞中表达 为方便起见,Lenti-X SARS-CoV-2 packaging mixes也可以单独购买。 |
|||||||||||||||||||||
■ 概述 | |||||||||||||||||||||
· 高性能包装系统有助于始终获得高病毒滴度:避免在试剂优化上花费时间,让您可以专注于下游分析 · 便捷的单管形式可大大减少动手时间和出错的可能性:操作简便,只需要将含有所选择转移质粒的水溶液,添加至包装细胞培养液中即可 · 包装混合物可以单独购买,也可以打包购买:节约资源,按需购买 · 提供中和试验对照:可使用试剂盒中的包装混合物,制备缺少包膜蛋白的慢病毒粒子,用作阴性对照 · 提供配套宿主细胞ACE2 cell line |
|||||||||||||||||||||
■ 实验例 | |||||||||||||||||||||
图1. 使用Lenti-X SARS-CoV-2 Packaging Single Shots制备假病毒操作流程。 |
|||||||||||||||||||||
图2. Lenti-X SARS-CoV-2 Packaging Single Shots (Universal)操作流程。 |
|||||||||||||||||||||
图3. 使用SARS-CoV-2假病毒转导ACE2-阳性细胞。Panel A. 使用Lenti-X SARS-CoV-2 Packaging Single Shots制备表达WT (Wuhan-Hu-1) 或者D614G变体刺突蛋白,同时也表达ZsGreen1绿色荧光蛋白质的假慢病毒粒子。每种病毒制剂取100 μl,转导稳定表达人ACE2受体的HEK293T细胞,HEK293T细胞培养在含有6 μg/ml polybrene 的48孔板中。转导后6天通过流式细胞术测定每个样品的转导效率。Panel B. 使用表达萤火虫荧光素酶的假病毒分别转导ACE2-阳性和不表达ACE2的HEK293T细胞(用于提供荧光素酶活性分析背景信号)。转导后6天测定荧光素酶活性。 |
|||||||||||||||||||||
图4. 测定使用Lenti-X SARS-CoV-2 Packaging Single Shots获得的功能滴度。Panel A.使用SARS-CoV-2假病毒转导ACE2-阳性HEK293T细胞,通过分析ZsGreen1荧光标记的表达情况测定功能滴度。Panel B. 感染后72小时,ACE2-阳性细胞的显微图像。 |
|||||||||||||||||||||
图5. 可溶性ACE2蛋白对携带SARS-CoV-2刺突蛋白变体假病毒的中和活性。Panels A and B. 梯度稀释融合IgG Fc结构域的可溶性ACE2蛋白(ACE2-Fc),与SARS-CoV-2假病毒作用于ACE2 HEK293T细胞。感染后3天检测荧光素酶表达水平,作为病毒感染性读数。数据以相对于仅病毒对照感染的中和作用百分比表示。数值为平均值±标准差,每个实验重复三次。 |
|||||||||||||||||||||
图6. 使用Lenti-X SARS-CoV-2 Packaging Single Shots制备D614G和B.1.351变异型SARS-CoV-2假病毒,测定其转导效率和感染滴度。使用Lenti-X SARS-CoV-2 Packaging Single Shots(B.1.351或D614G,全长或截短)制备表达ZsGreen1绿色荧光蛋白质的SARS-CoV-2假病毒。按照标准操作指导,使用Lenti-X Concentrator将病毒液浓缩50倍(B.1.351全长)或20倍(B.1.351截短和D614G),取不同体积病毒液转导HEK293T细胞,此细胞在48孔板中培养,含有6 μg/ml聚凝胺,能稳定表达人ACE2受体。在转导后6天通过流式细胞仪测定每个样品的转导效率(Panel A),并计算功能滴度(Panel B)。 |
|||||||||||||||||||||
图7. 使用Lenti-X Packaging Single Shots (Universal)制备的SARS-CoV-2假病毒转导ACE2-阳性细胞。使用Lenti-X Packaging Single Shots (Universal)制备表达截短的B.1.1.7 SARS-CoV-2刺突蛋白,同时也表达ZsGreen1绿色荧光蛋白质(Panel A)或者萤火虫荧光素酶(Panel B)的假型慢病毒粒子。Panel A. 使用浓缩后的病毒上清液(20X; 30 or 10 μl)转导稳定表达人ACE2受体的HEK293T细胞,HEK293T细胞培养在48孔板中,polybrene含量为6 μg/ml。转导后6天通过流式细胞术测定每个样品的转导效率。Panel B. 使用浓缩后的病毒上清液(20X; 30, 20, or 10 μl)分别转导稳定表达人ACE2受体的HEK293T细胞,HEK293T细胞培养在48孔板中,polybrene含量为6 μg/ml。转导缺少ACE2转基因的HEK293T细胞,以测定背景发光水平(NC,阴性对照)。转导后6天测定每个样品的发光值。 |
|||||||||||||||||||||
图8. 表达萤火虫荧光素酶的B.1.351 SARS-CoV-2假病毒转导ACE2 HEK293T细胞。使用Lenti-X SARS-CoV-2 Packaging Single Shots (B.1.351 spike, 全长或截短)制备表达萤火虫荧光素酶的假病毒。按照标准操作指导,使用Lenti-X Concentrator将病毒液浓缩20倍,取不同体积病毒液转导HEK293T细胞,此细胞在48孔板中培养,含有6 μg/ml聚凝胺,能稳定表达人ACE2受体。同时平行转导不表达ACE2受体的HEK293T细胞以确定背景发光水平,因为在缺乏ACE2受体的情况下,SARS-CoV-2假病毒无法感染HEK293T细胞。在转导3天后测定每个样品的发光值。 |
|||||||||||||||||||||
■ 制品内容 | |||||||||||||||||||||
Lenti-X SARS-CoV-2 Packaging Single Shots (WT Spike, Full Length)(Code No. 632668) | |||||||||||||||||||||
·Lenti-X SARS-CoV-2 Packaging Mix (WT Spike, Full Length) (Code No. 632672) ·Lenti-X SARS-CoV-2 Packaging Mix(No-Envelope Control) (Code No. 632676) ·Lenti-X Reporter Vector Set*1*2 |
|||||||||||||||||||||
Lenti-X SARS-CoV-2 Packaging Single Shots (D614G Spike, Full Length)(Code No. 632669) | |||||||||||||||||||||
·Lenti-X SARS-CoV-2 Packaging Mix (D614G Spike, Full Length) (Code No. 632673) ·Lenti-X SARS-CoV-2 Packaging Mix (No-Envelope Control) (Code No. 632676) ·Lenti-X Reporter Vector Set*1*2 |
|||||||||||||||||||||
Lenti-X SARS-CoV-2 Packaging Single Shots (B.1.351 Spike, Full Length)(Code No. 631292) | |||||||||||||||||||||
·Lenti-X SARS-CoV-2 Packaging Mix (B.1.351 Spike, Full Length) (Code No. 631290) ·Lenti-X SARS-CoV-2 Packaging Mix (No-Envelope Control) (Code No. 632676) ·Lenti-X Reporter Vector Set*1*2 |
|||||||||||||||||||||
Lenti-X SARS-CoV-2 Packaging Single Shots (WT Spike, Truncated)(Code No. 632670) | |||||||||||||||||||||
·Lenti-X SARS-CoV-2 Packaging Mix (WT Spike, Truncated) (Code No. 632674) ·Lenti-X SARS-CoV-2 Packaging Mix (No-Envelope Control) (Code No. 632676) ·Lenti-X Reporter Vector Set*1*2 |
|||||||||||||||||||||
Lenti-X SARS-CoV-2 Packaging Single Shots (D614G Spike, Truncated)(Code No. 632671) | |||||||||||||||||||||
·Lenti-X SARS-CoV-2 Packaging Mix (D614G Spike, Truncated) (Code No. 632675) ·Lenti-X SARS-CoV-2 Packaging Mix (No-Envelope Control) (Code No. 632676) ·Lenti-X Reporter Vector Set*1*2 |
|||||||||||||||||||||
Lenti-X SARS-CoV-2 Packaging Single Shots (B.1.351 Spike, Truncated)(Code No. 631293) | |||||||||||||||||||||
·Lenti-X SARS-CoV-2 Packaging Mix (B.1.351 Spike, Truncated) (Code No. 631291) ·Lenti-X SARS-CoV-2 Packaging Mix (No-Envelope Control) (Code No. 632676) ·Lenti-X Reporter Vector Set*1*2 |
|||||||||||||||||||||
Lenti-X SARS-CoV-2 Packaging Single Shots (Universal)(Code No. 631295)*3 | |||||||||||||||||||||
|
|||||||||||||||||||||
Lenti-X SARS-CoV-2 Packaging Mix (WT Spike, Full Length) (Code No. 632672) Lenti-X SARS-CoV-2 Packaging Mix (D614G Spike, Full Length) (Code No. 632673) Lenti-X SARS-CoV-2 Packaging Mix (B.1.351 Spike, Full Length) (Code No. 631290) Lenti-X SARS-CoV-2 Packaging Mix (WT Spike, Truncated) (Code No. 632674) Lenti-X SARS-CoV-2 Packaging Mix (D614G Spike, Truncated) (Code No. 632675) Lenti-X SARS-CoV-2 Packaging Mix (B.1.351 Spike, Truncated) (Code No. 631291) |
|||||||||||||||||||||
|
|||||||||||||||||||||
Lenti-X SARS-CoV-2 Packaging Mix (No-Envelope Control) (Code No. 632676) | |||||||||||||||||||||
|
|||||||||||||||||||||
*1 不单独销售。 | |||||||||||||||||||||
*2 Lenti-X Reporter Vector Set | |||||||||||||||||||||
|
|||||||||||||||||||||
*3 我们还提供不包含Lenti-X SARS-CoV-2 Spike Vector Set的产品。在不需要Lenti-X SARS-CoV-2 Spike Vector Set的场合下,请选择Lenti-X Packaging Single Shots (Envelope-Free)(Code No. 631294)。 | |||||||||||||||||||||
■ 保存 | |||||||||||||||||||||
-20℃ (各Lenti-X SARS-CoV-2 Packaging Mix保存在装有干燥剂的箔袋内) |
|||||||||||||||||||||
参考文献 | |||||||||||||||||||||
1. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Ni, L. et al. Immunity. (2020) 52, 971–977. 2. Cell entry mechanisms of SARS-CoV-2. Shang, J. et al. Proc Natl Acad Sci USA. (2020) 117, 11727–11734. 3. Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. Isabel, S. et al. Sci Rep. (2020) 10, 14031. 4. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. Johnson, MC. et al. J Virol. (2020) 94, e01062-20. |
|||||||||||||||||||||
产品详情请点击: | |||||||||||||||||||||
页面更新:2022-07-13 16:27:16